nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—CYP2D6—Fingolimod—multiple sclerosis	0.188	0.426	CbGbCtD
Moclobemide—CYP2C19—Prednisone—multiple sclerosis	0.0964	0.219	CbGbCtD
Moclobemide—CYP2C19—Dexamethasone—multiple sclerosis	0.0602	0.137	CbGbCtD
Moclobemide—CYP2C9—Dexamethasone—multiple sclerosis	0.05	0.114	CbGbCtD
Moclobemide—CYP2D6—Dexamethasone—multiple sclerosis	0.0457	0.104	CbGbCtD
Moclobemide—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.00233	0.0639	CbGpPWpGaD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00138	0.0378	CbGpPWpGaD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00138	0.0378	CbGpPWpGaD
Moclobemide—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00128	0.00245	CcSEcCtD
Moclobemide—Rash—Cladribine—multiple sclerosis	0.00127	0.00243	CcSEcCtD
Moclobemide—Hallucination—Betamethasone—multiple sclerosis	0.00127	0.00243	CcSEcCtD
Moclobemide—Hallucination—Dexamethasone—multiple sclerosis	0.00127	0.00243	CcSEcCtD
Moclobemide—Dermatitis—Cladribine—multiple sclerosis	0.00127	0.00243	CcSEcCtD
Moclobemide—Headache—Cladribine—multiple sclerosis	0.00126	0.00241	CcSEcCtD
Moclobemide—Vision blurred—Prednisolone—multiple sclerosis	0.00126	0.0024	CcSEcCtD
Moclobemide—Hypotension—Mitoxantrone—multiple sclerosis	0.00124	0.00237	CcSEcCtD
Moclobemide—Ill-defined disorder—Prednisolone—multiple sclerosis	0.00124	0.00236	CcSEcCtD
Moclobemide—Visual impairment—Dexamethasone—multiple sclerosis	0.00123	0.00235	CcSEcCtD
Moclobemide—Visual impairment—Betamethasone—multiple sclerosis	0.00123	0.00235	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00121	0.00231	CcSEcCtD
Moclobemide—Malaise—Prednisolone—multiple sclerosis	0.0012	0.0023	CcSEcCtD
Moclobemide—Dysgeusia—Triamcinolone—multiple sclerosis	0.0012	0.00229	CcSEcCtD
Moclobemide—Nausea—Cladribine—multiple sclerosis	0.0012	0.00229	CcSEcCtD
Moclobemide—Syncope—Prednisolone—multiple sclerosis	0.00119	0.00228	CcSEcCtD
Moclobemide—Paraesthesia—Mitoxantrone—multiple sclerosis	0.00119	0.00227	CcSEcCtD
Moclobemide—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00118	0.00226	CcSEcCtD
Moclobemide—Somnolence—Mitoxantrone—multiple sclerosis	0.00118	0.00225	CcSEcCtD
Moclobemide—Loss of consciousness—Prednisolone—multiple sclerosis	0.00117	0.00224	CcSEcCtD
Moclobemide—Dyspepsia—Mitoxantrone—multiple sclerosis	0.00117	0.00223	CcSEcCtD
Moclobemide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00115	0.0022	CcSEcCtD
Moclobemide—Hypertension—Prednisolone—multiple sclerosis	0.00115	0.0022	CcSEcCtD
Moclobemide—Fatigue—Mitoxantrone—multiple sclerosis	0.00114	0.00218	CcSEcCtD
Moclobemide—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00114	0.00217	CcSEcCtD
Moclobemide—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.00113	0.00217	CcSEcCtD
Moclobemide—Constipation—Mitoxantrone—multiple sclerosis	0.00113	0.00217	CcSEcCtD
Moclobemide—Bradycardia—Prednisone—multiple sclerosis	0.00113	0.00216	CcSEcCtD
Moclobemide—Diarrhoea—Azathioprine—multiple sclerosis	0.00112	0.00214	CcSEcCtD
Moclobemide—Discomfort—Prednisolone—multiple sclerosis	0.00112	0.00214	CcSEcCtD
Moclobemide—Hallucination—Prednisone—multiple sclerosis	0.00111	0.00211	CcSEcCtD
Moclobemide—Malaise—Triamcinolone—multiple sclerosis	0.0011	0.00211	CcSEcCtD
Moclobemide—Malaise—Methylprednisolone—multiple sclerosis	0.0011	0.00211	CcSEcCtD
Moclobemide—Syncope—Triamcinolone—multiple sclerosis	0.0011	0.0021	CcSEcCtD
Moclobemide—Syncope—Methylprednisolone—multiple sclerosis	0.0011	0.00209	CcSEcCtD
Moclobemide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00109	0.00209	CcSEcCtD
Moclobemide—Dysuria—Methotrexate—multiple sclerosis	0.00109	0.00207	CcSEcCtD
Moclobemide—Dizziness—Azathioprine—multiple sclerosis	0.00108	0.00207	CcSEcCtD
Moclobemide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00108	0.00207	CcSEcCtD
Moclobemide—Loss of consciousness—Triamcinolone—multiple sclerosis	0.00108	0.00206	CcSEcCtD
Moclobemide—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.00107	0.00205	CcSEcCtD
Moclobemide—Shock—Prednisolone—multiple sclerosis	0.00107	0.00204	CcSEcCtD
Moclobemide—Tachycardia—Prednisolone—multiple sclerosis	0.00106	0.00203	CcSEcCtD
Moclobemide—Hypertension—Triamcinolone—multiple sclerosis	0.00106	0.00202	CcSEcCtD
Moclobemide—Hypertension—Methylprednisolone—multiple sclerosis	0.00106	0.00202	CcSEcCtD
Moclobemide—Urticaria—Mitoxantrone—multiple sclerosis	0.00105	0.00201	CcSEcCtD
Moclobemide—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00105	0.00201	CcSEcCtD
Moclobemide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00105	0.002	CcSEcCtD
Moclobemide—Myalgia—Triamcinolone—multiple sclerosis	0.00104	0.00199	CcSEcCtD
Moclobemide—Vomiting—Azathioprine—multiple sclerosis	0.00104	0.00199	CcSEcCtD
Moclobemide—Myalgia—Methylprednisolone—multiple sclerosis	0.00104	0.00199	CcSEcCtD
Moclobemide—Anxiety—Methylprednisolone—multiple sclerosis	0.00104	0.00198	CcSEcCtD
Moclobemide—Drowsiness—Methotrexate—multiple sclerosis	0.00104	0.00198	CcSEcCtD
Moclobemide—Rash—Azathioprine—multiple sclerosis	0.00103	0.00198	CcSEcCtD
Moclobemide—Dermatitis—Azathioprine—multiple sclerosis	0.00103	0.00197	CcSEcCtD
Moclobemide—Flushing—Prednisone—multiple sclerosis	0.00103	0.00197	CcSEcCtD
Moclobemide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00103	0.00197	CcSEcCtD
Moclobemide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00103	0.00197	CcSEcCtD
Moclobemide—Discomfort—Triamcinolone—multiple sclerosis	0.00103	0.00197	CcSEcCtD
Moclobemide—Discomfort—Methylprednisolone—multiple sclerosis	0.00103	0.00196	CcSEcCtD
Moclobemide—Headache—Azathioprine—multiple sclerosis	0.00103	0.00196	CcSEcCtD
Moclobemide—Dry mouth—Triamcinolone—multiple sclerosis	0.00102	0.00195	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.00102	0.0279	CbGpPWpGaD
Moclobemide—Stomatitis—Methotrexate—multiple sclerosis	0.00101	0.00193	CcSEcCtD
Moclobemide—Conjunctivitis—Methotrexate—multiple sclerosis	0.00101	0.00192	CcSEcCtD
Moclobemide—Confusional state—Methylprednisolone—multiple sclerosis	0.00101	0.00192	CcSEcCtD
Moclobemide—Malaise—Betamethasone—multiple sclerosis	0.001	0.00192	CcSEcCtD
Moclobemide—Malaise—Dexamethasone—multiple sclerosis	0.001	0.00192	CcSEcCtD
Moclobemide—Syncope—Dexamethasone—multiple sclerosis	0.000997	0.0019	CcSEcCtD
Moclobemide—Syncope—Betamethasone—multiple sclerosis	0.000997	0.0019	CcSEcCtD
Moclobemide—Sweating—Methotrexate—multiple sclerosis	0.000993	0.0019	CcSEcCtD
Moclobemide—Shock—Triamcinolone—multiple sclerosis	0.000984	0.00188	CcSEcCtD
Moclobemide—Insomnia—Prednisolone—multiple sclerosis	0.000984	0.00188	CcSEcCtD
Moclobemide—Shock—Methylprednisolone—multiple sclerosis	0.000982	0.00188	CcSEcCtD
Moclobemide—Loss of consciousness—Betamethasone—multiple sclerosis	0.000977	0.00187	CcSEcCtD
Moclobemide—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000977	0.00187	CcSEcCtD
Moclobemide—Paraesthesia—Prednisolone—multiple sclerosis	0.000976	0.00187	CcSEcCtD
Moclobemide—Tachycardia—Triamcinolone—multiple sclerosis	0.000976	0.00186	CcSEcCtD
Moclobemide—Nausea—Azathioprine—multiple sclerosis	0.000974	0.00186	CcSEcCtD
Moclobemide—Tachycardia—Methylprednisolone—multiple sclerosis	0.000974	0.00186	CcSEcCtD
Moclobemide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000967	0.00185	CcSEcCtD
Moclobemide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000965	0.00184	CcSEcCtD
Moclobemide—Hypertension—Betamethasone—multiple sclerosis	0.00096	0.00183	CcSEcCtD
Moclobemide—Hypertension—Dexamethasone—multiple sclerosis	0.00096	0.00183	CcSEcCtD
Moclobemide—Asthenia—Mitoxantrone—multiple sclerosis	0.000951	0.00182	CcSEcCtD
Moclobemide—Myalgia—Dexamethasone—multiple sclerosis	0.000947	0.00181	CcSEcCtD
Moclobemide—Myalgia—Betamethasone—multiple sclerosis	0.000947	0.00181	CcSEcCtD
Moclobemide—Anxiety—Betamethasone—multiple sclerosis	0.000943	0.0018	CcSEcCtD
Moclobemide—Anxiety—Dexamethasone—multiple sclerosis	0.000943	0.0018	CcSEcCtD
Moclobemide—Discomfort—Betamethasone—multiple sclerosis	0.000935	0.00179	CcSEcCtD
Moclobemide—Discomfort—Dexamethasone—multiple sclerosis	0.000935	0.00179	CcSEcCtD
Moclobemide—Hypotension—Methylprednisolone—multiple sclerosis	0.000932	0.00178	CcSEcCtD
Moclobemide—Vision blurred—Prednisone—multiple sclerosis	0.000913	0.00174	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000911	0.00174	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000909	0.00174	CcSEcCtD
Moclobemide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000907	0.00173	CcSEcCtD
Moclobemide—Insomnia—Triamcinolone—multiple sclerosis	0.000904	0.00173	CcSEcCtD
Moclobemide—Insomnia—Methylprednisolone—multiple sclerosis	0.000902	0.00172	CcSEcCtD
Moclobemide—Ill-defined disorder—Prednisone—multiple sclerosis	0.000898	0.00172	CcSEcCtD
Moclobemide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000898	0.00172	CcSEcCtD
Moclobemide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000896	0.00171	CcSEcCtD
Moclobemide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000896	0.00171	CcSEcCtD
Moclobemide—Visual impairment—Methotrexate—multiple sclerosis	0.000896	0.00171	CcSEcCtD
Moclobemide—Shock—Dexamethasone—multiple sclerosis	0.000893	0.00171	CcSEcCtD
Moclobemide—Shock—Betamethasone—multiple sclerosis	0.000893	0.00171	CcSEcCtD
Moclobemide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000892	0.0017	CcSEcCtD
Moclobemide—Agitation—Prednisone—multiple sclerosis	0.00089	0.0017	CcSEcCtD
Moclobemide—Tachycardia—Dexamethasone—multiple sclerosis	0.000886	0.00169	CcSEcCtD
Moclobemide—Tachycardia—Betamethasone—multiple sclerosis	0.000886	0.00169	CcSEcCtD
Moclobemide—Dyspepsia—Triamcinolone—multiple sclerosis	0.00088	0.00168	CcSEcCtD
Moclobemide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000878	0.00168	CcSEcCtD
Moclobemide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000877	0.00168	CcSEcCtD
Moclobemide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000877	0.00168	CcSEcCtD
Moclobemide—Malaise—Prednisone—multiple sclerosis	0.000873	0.00167	CcSEcCtD
Moclobemide—Syncope—Prednisone—multiple sclerosis	0.000868	0.00166	CcSEcCtD
Moclobemide—Tinnitus—Methotrexate—multiple sclerosis	0.000867	0.00166	CcSEcCtD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000865	0.0237	CbGpPWpGaD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000865	0.0237	CbGpPWpGaD
Moclobemide—Urticaria—Prednisolone—multiple sclerosis	0.000864	0.00165	CcSEcCtD
Moclobemide—Fatigue—Triamcinolone—multiple sclerosis	0.000862	0.00165	CcSEcCtD
Moclobemide—Fatigue—Methylprednisolone—multiple sclerosis	0.00086	0.00164	CcSEcCtD
Moclobemide—Loss of consciousness—Prednisone—multiple sclerosis	0.000851	0.00163	CcSEcCtD
Moclobemide—Hypotension—Dexamethasone—multiple sclerosis	0.000848	0.00162	CcSEcCtD
Moclobemide—Hypotension—Betamethasone—multiple sclerosis	0.000848	0.00162	CcSEcCtD
Moclobemide—Vomiting—Mitoxantrone—multiple sclerosis	0.000843	0.00161	CcSEcCtD
Moclobemide—Hypertension—Prednisone—multiple sclerosis	0.000836	0.0016	CcSEcCtD
Moclobemide—Rash—Mitoxantrone—multiple sclerosis	0.000836	0.0016	CcSEcCtD
Moclobemide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000835	0.0016	CcSEcCtD
Moclobemide—Headache—Mitoxantrone—multiple sclerosis	0.00083	0.00159	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000827	0.00158	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000827	0.00158	CcSEcCtD
Moclobemide—Myalgia—Prednisone—multiple sclerosis	0.000824	0.00157	CcSEcCtD
Moclobemide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000824	0.00157	CcSEcCtD
Moclobemide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000822	0.00157	CcSEcCtD
Moclobemide—Anxiety—Prednisone—multiple sclerosis	0.000821	0.00157	CcSEcCtD
Moclobemide—Insomnia—Dexamethasone—multiple sclerosis	0.000821	0.00157	CcSEcCtD
Moclobemide—Insomnia—Betamethasone—multiple sclerosis	0.000821	0.00157	CcSEcCtD
Moclobemide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000816	0.00156	CcSEcCtD
Moclobemide—Paraesthesia—Betamethasone—multiple sclerosis	0.000815	0.00156	CcSEcCtD
Moclobemide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000815	0.00156	CcSEcCtD
Moclobemide—Discomfort—Prednisone—multiple sclerosis	0.000814	0.00156	CcSEcCtD
Moclobemide—Dyspepsia—Dexamethasone—multiple sclerosis	0.000799	0.00153	CcSEcCtD
Moclobemide—Dyspepsia—Betamethasone—multiple sclerosis	0.000799	0.00153	CcSEcCtD
Moclobemide—Urticaria—Triamcinolone—multiple sclerosis	0.000794	0.00152	CcSEcCtD
Moclobemide—Urticaria—Methylprednisolone—multiple sclerosis	0.000793	0.00151	CcSEcCtD
Moclobemide—Dysgeusia—Methotrexate—multiple sclerosis	0.000792	0.00151	CcSEcCtD
Moclobemide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000789	0.00151	CcSEcCtD
Moclobemide—Decreased appetite—Betamethasone—multiple sclerosis	0.000789	0.00151	CcSEcCtD
Moclobemide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000789	0.00151	CcSEcCtD
Moclobemide—Nausea—Mitoxantrone—multiple sclerosis	0.000787	0.0015	CcSEcCtD
Moclobemide—Fatigue—Betamethasone—multiple sclerosis	0.000782	0.00149	CcSEcCtD
Moclobemide—Fatigue—Dexamethasone—multiple sclerosis	0.000782	0.00149	CcSEcCtD
Moclobemide—Shock—Prednisone—multiple sclerosis	0.000777	0.00149	CcSEcCtD
Moclobemide—Tachycardia—Prednisone—multiple sclerosis	0.000771	0.00147	CcSEcCtD
Moclobemide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000764	0.00146	CcSEcCtD
Moclobemide—Vision blurred—Methotrexate—multiple sclerosis	0.000763	0.00146	CcSEcCtD
Moclobemide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000751	0.00143	CcSEcCtD
Moclobemide—Feeling abnormal—Betamethasone—multiple sclerosis	0.000748	0.00143	CcSEcCtD
Moclobemide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000748	0.00143	CcSEcCtD
Moclobemide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000742	0.00142	CcSEcCtD
Moclobemide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000742	0.00142	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—CYP27B1—multiple sclerosis	0.000733	0.0201	CbGpPWpGaD
Moclobemide—MAOB—Biological oxidations—CYP24A1—multiple sclerosis	0.000733	0.0201	CbGpPWpGaD
Moclobemide—Malaise—Methotrexate—multiple sclerosis	0.00073	0.00139	CcSEcCtD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000726	0.0199	CbGpPWpGaD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000726	0.0199	CbGpPWpGaD
Moclobemide—Urticaria—Dexamethasone—multiple sclerosis	0.000721	0.00138	CcSEcCtD
Moclobemide—Urticaria—Betamethasone—multiple sclerosis	0.000721	0.00138	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00072	0.00138	CcSEcCtD
Moclobemide—Dizziness—Prednisolone—multiple sclerosis	0.000719	0.00137	CcSEcCtD
Moclobemide—Asthenia—Triamcinolone—multiple sclerosis	0.000718	0.00137	CcSEcCtD
Moclobemide—Abdominal pain—Betamethasone—multiple sclerosis	0.000717	0.00137	CcSEcCtD
Moclobemide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000717	0.00137	CcSEcCtD
Moclobemide—Asthenia—Methylprednisolone—multiple sclerosis	0.000716	0.00137	CcSEcCtD
Moclobemide—Insomnia—Prednisone—multiple sclerosis	0.000715	0.00137	CcSEcCtD
Moclobemide—Paraesthesia—Prednisone—multiple sclerosis	0.00071	0.00136	CcSEcCtD
Moclobemide—Pruritus—Triamcinolone—multiple sclerosis	0.000708	0.00135	CcSEcCtD
Moclobemide—Pruritus—Methylprednisolone—multiple sclerosis	0.000706	0.00135	CcSEcCtD
Moclobemide—Dyspepsia—Prednisone—multiple sclerosis	0.000696	0.00133	CcSEcCtD
Moclobemide—MAOA—Serotonin Transporter Activity—IL1B—multiple sclerosis	0.000692	0.019	CbGpPWpGaD
Moclobemide—Myalgia—Methotrexate—multiple sclerosis	0.000689	0.00132	CcSEcCtD
Moclobemide—Chest pain—Methotrexate—multiple sclerosis	0.000689	0.00132	CcSEcCtD
Moclobemide—Decreased appetite—Prednisone—multiple sclerosis	0.000687	0.00131	CcSEcCtD
Moclobemide—Rash—Prednisolone—multiple sclerosis	0.000686	0.00131	CcSEcCtD
Moclobemide—Dermatitis—Prednisolone—multiple sclerosis	0.000685	0.00131	CcSEcCtD
Moclobemide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000683	0.0013	CcSEcCtD
Moclobemide—Fatigue—Prednisone—multiple sclerosis	0.000681	0.0013	CcSEcCtD
Moclobemide—Headache—Prednisolone—multiple sclerosis	0.000681	0.0013	CcSEcCtD
Moclobemide—Discomfort—Methotrexate—multiple sclerosis	0.000681	0.0013	CcSEcCtD
Moclobemide—Constipation—Prednisone—multiple sclerosis	0.000676	0.00129	CcSEcCtD
Moclobemide—Confusional state—Methotrexate—multiple sclerosis	0.000666	0.00127	CcSEcCtD
Moclobemide—Dizziness—Triamcinolone—multiple sclerosis	0.000661	0.00126	CcSEcCtD
Moclobemide—Dizziness—Methylprednisolone—multiple sclerosis	0.00066	0.00126	CcSEcCtD
Moclobemide—Feeling abnormal—Prednisone—multiple sclerosis	0.000651	0.00124	CcSEcCtD
Moclobemide—Asthenia—Dexamethasone—multiple sclerosis	0.000651	0.00124	CcSEcCtD
Moclobemide—Asthenia—Betamethasone—multiple sclerosis	0.000651	0.00124	CcSEcCtD
Moclobemide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000646	0.00123	CcSEcCtD
Moclobemide—Nausea—Prednisolone—multiple sclerosis	0.000646	0.00123	CcSEcCtD
Moclobemide—Pruritus—Dexamethasone—multiple sclerosis	0.000642	0.00123	CcSEcCtD
Moclobemide—Pruritus—Betamethasone—multiple sclerosis	0.000642	0.00123	CcSEcCtD
Moclobemide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000638	0.00122	CcSEcCtD
Moclobemide—Vomiting—Triamcinolone—multiple sclerosis	0.000636	0.00121	CcSEcCtD
Moclobemide—Vomiting—Methylprednisolone—multiple sclerosis	0.000634	0.00121	CcSEcCtD
Moclobemide—Rash—Triamcinolone—multiple sclerosis	0.000631	0.0012	CcSEcCtD
Moclobemide—Dermatitis—Triamcinolone—multiple sclerosis	0.00063	0.0012	CcSEcCtD
Moclobemide—Rash—Methylprednisolone—multiple sclerosis	0.000629	0.0012	CcSEcCtD
Moclobemide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000629	0.0012	CcSEcCtD
Moclobemide—Urticaria—Prednisone—multiple sclerosis	0.000628	0.0012	CcSEcCtD
Moclobemide—Headache—Triamcinolone—multiple sclerosis	0.000626	0.0012	CcSEcCtD
Moclobemide—Headache—Methylprednisolone—multiple sclerosis	0.000625	0.00119	CcSEcCtD
Moclobemide—Abdominal pain—Prednisone—multiple sclerosis	0.000625	0.00119	CcSEcCtD
Moclobemide—Diarrhoea—Betamethasone—multiple sclerosis	0.000621	0.00119	CcSEcCtD
Moclobemide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000621	0.00119	CcSEcCtD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00062	0.017	CbGpPWpGaD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00062	0.017	CbGpPWpGaD
Moclobemide—Hypotension—Methotrexate—multiple sclerosis	0.000617	0.00118	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000602	0.00115	CcSEcCtD
Moclobemide—Dizziness—Dexamethasone—multiple sclerosis	0.0006	0.00115	CcSEcCtD
Moclobemide—Dizziness—Betamethasone—multiple sclerosis	0.0006	0.00115	CcSEcCtD
Moclobemide—Insomnia—Methotrexate—multiple sclerosis	0.000597	0.00114	CcSEcCtD
Moclobemide—Nausea—Triamcinolone—multiple sclerosis	0.000594	0.00113	CcSEcCtD
Moclobemide—Paraesthesia—Methotrexate—multiple sclerosis	0.000593	0.00113	CcSEcCtD
Moclobemide—Nausea—Methylprednisolone—multiple sclerosis	0.000593	0.00113	CcSEcCtD
Moclobemide—Dyspnoea—Methotrexate—multiple sclerosis	0.000589	0.00112	CcSEcCtD
Moclobemide—Somnolence—Methotrexate—multiple sclerosis	0.000587	0.00112	CcSEcCtD
Moclobemide—Dyspepsia—Methotrexate—multiple sclerosis	0.000581	0.00111	CcSEcCtD
Moclobemide—Vomiting—Dexamethasone—multiple sclerosis	0.000577	0.0011	CcSEcCtD
Moclobemide—Vomiting—Betamethasone—multiple sclerosis	0.000577	0.0011	CcSEcCtD
Moclobemide—Decreased appetite—Methotrexate—multiple sclerosis	0.000574	0.0011	CcSEcCtD
Moclobemide—Rash—Betamethasone—multiple sclerosis	0.000572	0.00109	CcSEcCtD
Moclobemide—Rash—Dexamethasone—multiple sclerosis	0.000572	0.00109	CcSEcCtD
Moclobemide—Dermatitis—Dexamethasone—multiple sclerosis	0.000572	0.00109	CcSEcCtD
Moclobemide—Dermatitis—Betamethasone—multiple sclerosis	0.000572	0.00109	CcSEcCtD
Moclobemide—Fatigue—Methotrexate—multiple sclerosis	0.000569	0.00109	CcSEcCtD
Moclobemide—Headache—Dexamethasone—multiple sclerosis	0.000568	0.00109	CcSEcCtD
Moclobemide—Headache—Betamethasone—multiple sclerosis	0.000568	0.00109	CcSEcCtD
Moclobemide—Asthenia—Prednisone—multiple sclerosis	0.000567	0.00108	CcSEcCtD
Moclobemide—Pruritus—Prednisone—multiple sclerosis	0.000559	0.00107	CcSEcCtD
Moclobemide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000544	0.00104	CcSEcCtD
Moclobemide—Diarrhoea—Prednisone—multiple sclerosis	0.000541	0.00103	CcSEcCtD
Moclobemide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.00054	0.00103	CcSEcCtD
Moclobemide—Nausea—Betamethasone—multiple sclerosis	0.000539	0.00103	CcSEcCtD
Moclobemide—Nausea—Dexamethasone—multiple sclerosis	0.000539	0.00103	CcSEcCtD
Moclobemide—Urticaria—Methotrexate—multiple sclerosis	0.000525	0.001	CcSEcCtD
Moclobemide—Dizziness—Prednisone—multiple sclerosis	0.000523	0.000998	CcSEcCtD
Moclobemide—Abdominal pain—Methotrexate—multiple sclerosis	0.000522	0.000997	CcSEcCtD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000505	0.0139	CbGpPWpGaD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000505	0.0139	CbGpPWpGaD
Moclobemide—Vomiting—Prednisone—multiple sclerosis	0.000502	0.00096	CcSEcCtD
Moclobemide—MAOA—Melatonin metabolism and effects—APOE—multiple sclerosis	0.0005	0.0137	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000499	0.0137	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000499	0.0137	CbGpPWpGaD
Moclobemide—Rash—Prednisone—multiple sclerosis	0.000498	0.000952	CcSEcCtD
Moclobemide—Dermatitis—Prednisone—multiple sclerosis	0.000498	0.000951	CcSEcCtD
Moclobemide—Headache—Prednisone—multiple sclerosis	0.000495	0.000946	CcSEcCtD
Moclobemide—MAOA—Neuronal System—KCNA3—multiple sclerosis	0.000484	0.0133	CbGpPWpGaD
Moclobemide—Asthenia—Methotrexate—multiple sclerosis	0.000474	0.000905	CcSEcCtD
Moclobemide—Nausea—Prednisone—multiple sclerosis	0.000469	0.000897	CcSEcCtD
Moclobemide—Pruritus—Methotrexate—multiple sclerosis	0.000467	0.000893	CcSEcCtD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000465	0.0127	CbGpPWpGaD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000465	0.0127	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000461	0.0126	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000461	0.0126	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP24A1—multiple sclerosis	0.00046	0.0126	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP27B1—multiple sclerosis	0.00046	0.0126	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000459	0.0126	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000459	0.0126	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000455	0.0125	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000455	0.0125	CbGpPWpGaD
Moclobemide—Diarrhoea—Methotrexate—multiple sclerosis	0.000452	0.000863	CcSEcCtD
Moclobemide—Dizziness—Methotrexate—multiple sclerosis	0.000437	0.000834	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000423	0.0116	CbGpPWpGaD
Moclobemide—Vomiting—Methotrexate—multiple sclerosis	0.00042	0.000802	CcSEcCtD
Moclobemide—Rash—Methotrexate—multiple sclerosis	0.000416	0.000796	CcSEcCtD
Moclobemide—Dermatitis—Methotrexate—multiple sclerosis	0.000416	0.000795	CcSEcCtD
Moclobemide—Headache—Methotrexate—multiple sclerosis	0.000414	0.00079	CcSEcCtD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00041	0.0112	CbGpPWpGaD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00041	0.0112	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000394	0.0108	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000394	0.0108	CbGpPWpGaD
Moclobemide—Nausea—Methotrexate—multiple sclerosis	0.000392	0.000749	CcSEcCtD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000388	0.0107	CbGpPWpGaD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000388	0.0107	CbGpPWpGaD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000377	0.0103	CbGpPWpGaD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000377	0.0103	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000373	0.0102	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000373	0.0102	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000337	0.00926	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.00032	0.00879	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000319	0.00875	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000319	0.00875	CbGpPWpGaD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00031	0.00851	CbGpPWpGaD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000237	0.00651	CbGpPWpGaD
Moclobemide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000237	0.00649	CbGpPWpGaD
Moclobemide—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000218	0.00597	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000218	0.00597	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000218	0.00597	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000215	0.00589	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000215	0.00589	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000212	0.00581	CbGpPWpGaD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000203	0.00557	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.0002	0.00549	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.0002	0.00549	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000198	0.00544	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000198	0.00544	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000197	0.00541	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000197	0.00541	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000196	0.00537	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000196	0.00537	CbGpPWpGaD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000195	0.00534	CbGpPWpGaD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000187	0.00514	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000184	0.00506	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—SRM—multiple sclerosis	0.000178	0.00488	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000177	0.00486	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.00017	0.00465	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.00017	0.00465	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000167	0.00459	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000167	0.00459	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000166	0.00455	CbGpPWpGaD
Moclobemide—MAOB—Biological oxidations—POMC—multiple sclerosis	0.000165	0.00452	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000158	0.00434	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—BCHE—multiple sclerosis	0.000136	0.00373	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP24A1—multiple sclerosis	0.000125	0.00344	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP27B1—multiple sclerosis	0.000125	0.00344	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GPC5—multiple sclerosis	0.000115	0.00314	CbGpPWpGaD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000114	0.00312	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—SRM—multiple sclerosis	0.000112	0.00306	CbGpPWpGaD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000105	0.00287	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000104	0.00284	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—POMC—multiple sclerosis	0.000103	0.00284	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—RRM1—multiple sclerosis	9.49e-05	0.0026	CbGpPWpGaD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.21e-05	0.00253	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	9.11e-05	0.0025	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.86e-05	0.00243	CbGpPWpGaD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.47e-05	0.00232	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.4e-05	0.0023	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.35e-05	0.00229	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.35e-05	0.00229	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	8.3e-05	0.00228	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	8.13e-05	0.00223	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	8.1e-05	0.00222	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP24A1—multiple sclerosis	7.86e-05	0.00216	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP27B1—multiple sclerosis	7.86e-05	0.00216	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.62e-05	0.00209	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.62e-05	0.00209	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GPC5—multiple sclerosis	7.19e-05	0.00197	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.18e-05	0.00197	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.51e-05	0.00179	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.51e-05	0.00179	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	6.33e-05	0.00174	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	6.32e-05	0.00173	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	6.19e-05	0.0017	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—TNF—multiple sclerosis	6.02e-05	0.00165	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—RRM1—multiple sclerosis	5.96e-05	0.00163	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	5.9e-05	0.00162	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	5.9e-05	0.00162	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—BCHE—multiple sclerosis	5.45e-05	0.0015	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—SRM—multiple sclerosis	5.28e-05	0.00145	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	5.18e-05	0.00142	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	4.89e-05	0.00134	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL6—multiple sclerosis	4.86e-05	0.00133	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—SRM—multiple sclerosis	4.86e-05	0.00133	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—SRM—multiple sclerosis	4.82e-05	0.00132	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—POMC—multiple sclerosis	4.5e-05	0.00123	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	4.46e-05	0.00122	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—SRM—multiple sclerosis	4.11e-05	0.00113	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—MAPK1—multiple sclerosis	3.97e-05	0.00109	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—POMC—multiple sclerosis	3.81e-05	0.00105	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	3.72e-05	0.00102	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	3.72e-05	0.00102	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.64e-05	0.000998	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	3.42e-05	0.000939	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	3.42e-05	0.000939	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—BCHE—multiple sclerosis	3.42e-05	0.000939	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GPC5—multiple sclerosis	3.4e-05	0.000934	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	3.39e-05	0.000931	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	3.39e-05	0.000931	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.32e-05	0.00091	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—APOE—multiple sclerosis	3.28e-05	0.0009	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GPC5—multiple sclerosis	3.13e-05	0.000859	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GPC5—multiple sclerosis	3.1e-05	0.000851	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	2.9e-05	0.000795	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	2.9e-05	0.000795	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.83e-05	0.000777	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.82e-05	0.000774	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—POMC—multiple sclerosis	2.82e-05	0.000773	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GPC5—multiple sclerosis	2.65e-05	0.000727	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.59e-05	0.000711	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.57e-05	0.000705	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—ALB—multiple sclerosis	2.57e-05	0.000705	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—RRM1—multiple sclerosis	2.2e-05	0.000603	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.19e-05	0.0006	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—APOE—multiple sclerosis	2.06e-05	0.000565	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.99e-05	0.000547	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.88e-05	0.000516	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—POMC—multiple sclerosis	1.77e-05	0.000485	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.71e-05	0.00047	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.71e-05	0.00047	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.7e-05	0.000468	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.62e-05	0.000444	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ALB—multiple sclerosis	1.61e-05	0.000442	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.56e-05	0.000429	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.49e-05	0.000409	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.48e-05	0.000405	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.46e-05	0.000402	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.34e-05	0.000366	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.26e-05	0.000346	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—APOE—multiple sclerosis	9.74e-06	0.000267	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—APOE—multiple sclerosis	8.96e-06	0.000246	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—APOE—multiple sclerosis	8.88e-06	0.000244	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—POMC—multiple sclerosis	8.37e-06	0.00023	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—POMC—multiple sclerosis	7.7e-06	0.000211	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—POMC—multiple sclerosis	7.63e-06	0.000209	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ALB—multiple sclerosis	7.63e-06	0.000209	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—APOE—multiple sclerosis	7.59e-06	0.000208	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ALB—multiple sclerosis	7.02e-06	0.000193	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ALB—multiple sclerosis	6.96e-06	0.000191	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—POMC—multiple sclerosis	6.52e-06	0.000179	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ALB—multiple sclerosis	5.95e-06	0.000163	CbGpPWpGaD
